Low traffic neighbourhoods
We are introducing people-friendly streets neighbourhoods, sometimes called low traffic neighbourhoods (LTNs), to the borough. By installing inexpensive measures like bollards and smart cameras, we are creating more space for everyone to enjoy their neighbourhoods as they walk, wheel and cycle around.
These schemes are being installed as 18-month trials and residents are being asked for their views on whether the measures should remain in place permanently roughly 12 months after the start of the trial. It’s important that we allow enough time for you to experience the changes and for traffic patterns to settle down.
Residents and visitors can still access their street by motor vehicle and receive deliveries. However, it will be much harder or impossible for traffic to cut through local streets from one main road to the next.
You can see maps of all our LTNs on the dedicated neighbourhood pages below or access our Google map of the LTN's and School Streets.
Your low-traffic neighbourhoods
Find out more about the low traffic neighbourhood in your area.
Have your say
Local people know their areas best and we want to hear your views on how to make your area more people-friendly.
Our Commonplace website has been an effective way to gather views on how you want to make Islington’s street more people-friendly and we appreciate the time residents have taken to share their comments.
We have now moved onto the next phase of the trials and held public consultations roughly 12 months after the start of each low traffic neighbourhood trial. We have consulted on the following schemes and you can find the outcomes of the consultations on the individual areas webpages (links above): St Peter's, Canonbury East, Clerkenwell Green, Canonbury West and Amwell.
We introduced the St Mary's Church scheme in February 2022. We will hold a public consultation on this scheme around 12 months after the trial began. You can leave feedback on the scheme through the feedback survey. Your feedback is invaluable to us and we thank everyone who has provided feedback throughout the trials.